Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	14/LO/2182	143226	A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC) (protocol ID: TS103) STOP study	Number Agreed	4	4	Date Agreed	31/01/2018	4	08/09/2017	4	Recruitment finished	
2	16/NE/0057	199733	Safety & Efficacy of Tideglusib in Type 1 Myotonic Dystrophy	Range Agreed	8	16	Date Agreed	31/08/2017	16	31/08/2017	16	Recruitment finished	
3	16/EM/0125	198595	Powered Vascular Stapler use in Renal Surgery	Range Agreed	20	45	Date Agreed	31/08/2017	41	25/07/2017	41	Recruitment finished	
4	16/NE/0023	218003	CREAD: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Number Agreed	2	2	Date Agreed	31/07/2018	2	01/09/2017	2	Recruitment finished	
5	16/ES/0026	198532	Effectiveness of adalimumab in moderate to severe HidrAdenitis SuppuRativa patients - a Multi cOuNtrY study in real life setting - HARMONY Study	Number Agreed	5	5	Date Agreed	31/03/2018	5	08/09/2017	5	Recruitment finished	
6	14/NI/1033	147734	A Phase 1 open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours	Number Agreed	10	10	Date Agreed	27/12/2018	9	19/07/2017	9	Withdrawn by sponsor	Competitive recruitment by sponsor
7	16/SC/0542	208245	A multicener, Open-Label, Extension Study To Evaluate The Long-Term Safety And Tolerability Of Lampalizumab In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration Who Have Completed A Roche-Sponsored Study.	Number Agreed	1	1	Date Agreed	30/09/2017	1	06/09/2017	1	Recruitment finished	
8	17/LO/0212	221502	An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)	Number Agreed	3	3	Date Agreed	31/07/2017	3	31/07/2017	3	Recruitment finished	
9	16/NE/0259	209692	Open label, Extension Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type-1 Deficiency Syndrome	Number Agreed	2	2	Date Agreed	15/09/2017	2	15/09/2017	2	Recruitment finished	
10	16/NW/0787	216022	A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (class III) mutation	Range Agreed	1	2	Date Agreed	18/08/2017	1	18/08/2017	1	Recruitment finished	
11	17/EM/0006	216496	A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine	Range Agreed	1	3	Date Agreed	05/10/2017	1	07/07/2017	1	Withdrawn by sponsor	Competitive recruitment by sponsor
12	16/NE/0031	193654	Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic response of Foxy-5 in Patients with Metastatic Breast-, Colon- or Prostate Cancer.	Number Agreed	8	8	Date Agreed	31/08/2017	3	31/08/2017	3	Recruitment finished	Rectal patients were not eligible as a new standard treatment became available, so referrals dried-up. The sponsor opened the UK-only slots to Denmark

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
13	16/ES/0004	192492	A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors	Number Agreed	5	5	Date Agreed	30/09/2017	4	30/09/2017	4	Recruitment finished	Several patients were screened but unfortunaltely only 4 patients were suitable for the study
14	16/WS/0109	199365	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neruoopathic Pain From Lumbosacral Radiculopathy	Number Agreed	1	1	Date Agreed	08/08/2017	0	08/08/2017	0	Recruitment finished	Unable to find a suitable patient who fitted the study criteria
15	15/WS/0160	174507	Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated with Heart Failure	Range Agreed	3	6	Date Agreed	30/09/2017	1	31/07/2017	1	Withdrawn by sponsor	By the time the study was initiated the trial was almost complete and patients suitable were difficult to identify
16	11/EM/0398	87747	A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus)	Number Agreed	1	1	Date Agreed	03/07/2017	1	02/07/2017	1	Recruitment finished	
17	13/SC/0173	108971	VIABLE: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostrate Cancer Eligible for 1st Line Chemotherapy	Range Agreed	6	8	Date Agreed	16/11/2018	6	07/10/2017	6	Recruitment finished	
18	15/NE/0204	182876	PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-a (TARGAXAN®/XIFAXAN®)550 mg	Range Agreed	4	12	Date Agreed	31/12/2017	11	30/09/2017	11	Recruitment finished	
19	15/LO/1118	180199	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers	Number Agreed	5	5	Date Agreed	30/06/2025	1	18/12/2017	1	Withdrawn by sponsor	Sponsor closed enrollment to the study because the initial data appeard there was linited or no significant benefit of treatment with GSK525762 as a single agent in subjects
20	14/SC/1161	17382	Prospective,single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Range Agreed	50	100	Date Agreed	31/05/2018	100	30/11/2017	100	Recruitment finished	
21	15/LO/1289	18607	Multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures	Range Agreed	5	8	Date Agreed	31/01/2018	6	12/12/2017	6	Recruitment finished	
22	15/EE/0301	173689	A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and the association with Hemophilia A and its treatment in patients with moderate to severe Hemophilia A.	Range Agreed	10	40	Date Agreed	31/08/2018	41	04/12/2017	41	Recruitment finished	
23	15/WS/0282	18747	Safety & Efficacy of Lenalidomide with MOR00208 in R-R DLBCL Patients	Range Agreed	2	6	Date Agreed	31/10/2017	3	31/10/2017	3	Recruitment finished	
24	15/LO/0781	171789	Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patients	Number Agreed	1	1	Date Agreed	01/11/2017	1	01/11/2017	1	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
25	15/SC/0456	174561	An Early-Phase, Multicenter, Open-Label Study Of The Safety And Pharmacokinetics Of Anti-PD-L1 Antibody (MPDL3280A) In Pediatric And Young Adult Patients With Previously Treated Solid Tumors	Range Agreed	1	3	Date Agreed	30/09/2017	1	29/09/2017	1	Recruitment finished	
26	16/NW/0238	183403	DRAKO Non-interventional Study	Range Agreed	10	25	Date Agreed	31/12/2017	10	31/12/2017	10	Recruitment finished	
27	17/ES/0030	216486	PHASE IV OPEN LABEL SINGLE GROUP ONE YEAR STUDY OF HOME SELF-INJECTION WITH SAYANA® PRESS IN ADULT WOMEN OF REPRODUCTIVE AGE	Number Agreed	10	10	Date Agreed	20/04/2018	1	01/12/2017	1	Withdrawn by sponsor	Main site reached their target and therefore closed the study earlier than planned
28	16/EM/0007	190428	Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes.	Number Agreed	4	4	Date Agreed	31/12/2018	4	02/10/2017	4	Recruitment finished	
29	16/NS/0070	208445	The HeartFlow ADVANCE Registry: Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE	Range Agreed	3	6	Date Agreed	29/06/2021	4	31/10/2017	4	Recruitment finished	
30	16/LO/0803	204170	Study of MiniMed™ 640G Insulin Pump with SmartGuard™ in prevention of Low Glucose Events in adults with Type 1 diabetes	Number Agreed	7	7	Date Agreed	01/12/2017	0	01/12/2017	0	Withdrawn by sponsor	No patients were recruited and Newcastle was closed as a site by the sponsor
31	16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Number Agreed	4	4	Date Agreed	31/10/2017	1	09/10/2017	1	Recruitment finished	Only one patient from the original study was eligible to continue
32	16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	Range Agreed	1	3	Date Agreed	21/12/2017	1	13/12/2017	1	Recruitment finished	
33	17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Range Agreed	3	6	Date Agreed	30/06/2018	0	20/11/2017	0	Withdrawn by sponsor	The sponsor discontinued the tozadenant development program, an investigaional treatment for Parkinson's disease. Based on new information obtained from the Phase 3 program relating to previously agranulocytosis and associated serious adverse events.
34	16/NE/0386	217871	VBP15-002 A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)	Range Agreed	4	6	Date Agreed	31/10/2017	6	31/08/2017	6	Recruitment finished	
35	16/NE/0387	218683	Amended Clinical Protocol #1 for a Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD).	Number Agreed	7	7	Date Agreed	02/03/2018	7	31/10/2017	7	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
36	16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Number Agreed	3	3	Date Agreed	31/01/2018	1	06/11/2017	1	Withdrawn by sponsor	Newcastle recruited one patient before the study was closed by the sponsor
37	16/NE/0311	211096	A real world study to describe the impact of AbbVie Care on patient quality of life and experience and NHS resource use in inflammatory bowel disease, rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis in the UK (AMORE)	Number Agreed	6	6	Date Agreed	30/11/2017	6	14/09/2017	6	Recruitment finished	
38	16/SC/0676	217183	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis	Number Agreed	1	1	Date Agreed	31/10/2017	0	31/10/2017	0	Recruitment finished	The clinical team were actively looking for paients however, they didn't identify any in clinic who fitted the strict eligibilty critera
39	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Number Agreed	1	1	Date Agreed	31/05/2018	1	12/10/2017	1	Recruitment finished	
40	16/WM/0433	215494	A research study to describe the "real world" use of Thrombopoietin-Receptor Agonists (TRAs) in the management of Immune Thrombocytopenia (ITp) in the UK	Number Agreed	10	10	Date Agreed	31/10/2017	10	31/10/2017	10	Recruitment finished	
41	17/NE/0270	231054	Serum sample collection to determine analytical performance characteristics of the ADVIA CENTAUR® Free Beta Human Chorionic Gonadotropin assay	Number Agreed	150	150	Date Agreed	16/02/2018	173	19/12/2017	173	Recruitment finished	
42	17/NE/0201	218005	A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)	Number Agreed	5	5	Date Agreed	31/08/2018	9	06/09/2017	9	Recruitment finished	
43	16/EE/0357	206501	Opicapone in clinical practice	Range Agreed	4	8	Date Agreed	13/12/2017	4	13/12/2017	4	Recruitment finished	
44	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of multiple sclerosis	Number Agreed	3	3	Date Agreed	27/12/2017	0	14/12/2017	0	Withdrawn by sponsor	Due to fast Global recruitment the sponsor was able to close the study early. No patients were recruited at Newcastle
45	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	3	3	Date Agreed	31/12/2017	0	31/12/2017	0	Withdrawn by sponsor	The sponsor closed the arm of the trail that was going to use their microbeads a form of Intra venous placement- worldwide. They are now looking at developing a treatment in partnership with clot retrial equipment to use the microbeads in the inter arterial form

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
46	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Range Agreed	1	4	Date Agreed	12/12/2017	3	12/12/2017	3	Recruitment finished	
47	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Range Agreed	2	6	Date Agreed	31/05/2018	2	12/03/2018	2	Withdrawn by sponsor	Competitive recruitment by sponsor
48	17/LO/0096	220205	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)	Number Agreed	4	4	Date Agreed	01/04/2018	0	08/03/2018	0	Withdrawn by sponsor	Sponsor closed study early following announcement of voluntary worldwide withdrawal of ZINBRYTA (daclizumab) for relapsing multiple sclerosis.
49	12/LO/1257	105896	UTCPH310: Oral UT-15C for treatment of Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	6	Date Agreed	30/04/2018	7	31/12/2017	7	Recruitment finished	
50	15/LO/1226	163213	Onyx CFZ008: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Number Agreed	1	1	Date Agreed	22/09/2017	0	22/09/2017	0	Withdrawn by sponsor	Due to contractual difficulties Newcastle's site was closed early
51	16/EM/0512	215840	A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION–POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA	Range Agreed	1	3	Date Agreed	31/10/2018	1	30/03/2018	1	Recruitment finished	
52	16/NE/0321	211563	A Phase 2, Double-Blind, Placebo-Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome	Range Agreed	14	28	Date Agreed	01/02/2018	22	01/02/2018	22	Recruitment finished	
53	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	20	Date Agreed	01/02/2018	25	01/02/2018	25	Recruitment finished	
54	15/LO/1950	184545	A Randomized Placebo Controlled Phase 2b/3 Study of ABT-414 in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)	Range Agreed	1	5	Date Agreed	20/04/2018	2	15/01/2018	2	Recruitment finished	
55	16/SC/0677	217105	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis	Number Agreed	2	2	Date Agreed	31/10/2017	0	31/10/2017	0	Withdrawn by sponsor	No patients was identified due to the strict eligibility criteria
56	15/NE/0143	174391	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Range Agreed	2	3	Date Agreed	17/11/2017	2	17/11/2017	2	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
57	15/NW/0592	185435	randomised, double-blinded, double-dummy, placebo-controlled, parallel-group multi-centre exploratory clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus (T1DM) investigating the effect of the IMP and a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) on beta-cell preservation	Range Agreed	1	2	Date Agreed	01/09/2017	4	01/09/2017	4	Recruitment finished	
58	16/SC/0530	213306	Evaluating the tolerance, compliance, acceptability and safety of Ketocal 2.5:1 LQ, a nutritionally complete liquid feed for use as part of the Ketogenic Diet in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated	Number Agreed	3	3	Date Agreed	13/12/2018	3	30/03/2018	3	Recruitment finished	
59	17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Number Agreed	3	3	Date Agreed	30/01/2019	4	31/01/2018	4	Recruitment finished	
60	16/WM/0409	204629	Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Range Agreed	6	10	Date Agreed	15/01/2018	7	15/01/2018	7	Recruitment finished	
61	17/LO/1147	222154	Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2 (ECZema TRAlokinumab trial no. 2)	Number Agreed	6	6	Date Agreed	01/07/2018	7	23/03/2018	7	Recruitment finished	
62	16/WM/0471	215399	An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)	Range Agreed	2	4	Date Agreed	15/07/2018	4	30/03/2018	4	Recruitment finished	
63	17/WS/0165	226413	A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 Infection and Aspartate aminotransferase to Platelet Ratio Index (APRI) ≤ 1	Range Agreed	2	6	Date Agreed	24/01/2018	5	24/01/2018	5	Recruitment finished	
64	17/NI/0367	237110	A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	7	7	Date Agreed	05/05/2020	7	16/03/2018	7	Recruitment finished	
65	17/SC/0028	218036	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Number Agreed	4	4	Date Agreed	30/03/2018	1	26/02/2018	1	Recruitment finished	Competitive recruitment by sponsor meant the study closed early than planned

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
66	15/LO/1480	186764	Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns (HOLOCORE)	Range Agreed	3	5	Date Agreed	31/01/2019	5	30/05/2018	5	Recruitment finished	
67	17/NE/0019	212701	SharkCore biopsy needle versus standard FNA needle in the diagnosis of solid pancreatic masses a randomised controlled cross-over trial of EUS guided tissue acquisition - The SharkBITE study	Number Agreed	108	108	Date Agreed	31/05/2018	108	31/05/2018	108	Recruitment finished	
68	16/WM/0473	213847	A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Range Agreed	3	11	Date Agreed	26/02/2018	9	26/02/2018	9	Recruitment finished	
69	15/WA/0465	189501	Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds	Number Agreed	10	10	Date Agreed	19/06/2018	2	19/06/2018	2	Withdrawn by sponsor	Sponsor withdrew study due to urgent safety measures
70	16/YH/0186	200765	A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)	Number Agreed	5	5	Date Agreed	30/04/2018	2	30/04/2018	2	Withdrawn by sponsor	Sponsor closed the study due to high screen failure rates
71	15/SC/0659	189114	A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer's Dementia	Range Agreed	3	6	Date Agreed	31/08/2018	0	17/05/2018	0	Withdrawn by sponsor	Sponsor took the decision to close the study because of the benefit-risk was no longer favourable to continue development of atabecestat in individuals with preclinical sporadic AD
72	16/ES/0100	195249	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (CF) Being Treated for an Exacerbation of CF-associated Lung Disease	Range Agreed	1	6	Date Agreed	31/03/2018	6	31/03/2018	6	Recruitment finished	
73	15/SS/0148	181087	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab BIIB037 in Subjects with Early Symptomatic Alzheimer's Disease	Number Agreed	3	3	Date Agreed	28/02/2018	3	28/02/2018	3	Recruitment finished	
74	16/EM/0436	213166	SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)	Number Agreed	1	1	Date Agreed	28/02/2018	0	28/02/2018	0	Withdrawn by sponsor	Recruitment was met globally before the Nuth site was able to consent a patient

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
75	16/EE/0358	212839	A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infection	Number Agreed	3	3	Date Agreed	13/04/2018	3	13/04/2018	3	Recruitment finished	
76	16/LO/1589	200691	A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WELL DIFFERENTIATED, METASTATIC AND/OR UNRESECTABLE TYPICAL OR ATYPICAL LUNG NEUROENDOCRINE TUMORS	Number Agreed	4	4	Date Agreed	30/06/2018	0	30/06/2018	0	Withdrawn by sponsor	Despite all efforts and resources invested to overcome recruitment challenges the sponsor toke the decision to end patient enrollment in the study
77	16/WM/0507	218607	A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis	Number Agreed	2	2	Date Agreed	17/04/2018	2	17/04/2018	2	Recruitment finished	
78	17/EE/0071	201502	Direct Implantation of the SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System (IDS) with Bioresorbable Drug Carrier Technology The DIRECT III Post Market Study	Range Agreed	3	50	Date Agreed	31/12/2017	15	31/12/2017	15	Recruitment finished	
79	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	Range Agreed	6	12	Date Agreed	28/04/2018	6	28/04/2018	6	Recruitment finished	
80	17/SC/0294	224828	Title: A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer	Number Agreed	3	3	Date Agreed	12/06/2018	3	12/06/2018	3	Recruitment finished	
81	17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Range Agreed	2	3	Date Agreed	30/01/2019	2	30/01/2018	2	Recruitment finished	
82	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	4	26/06/2018	4	Recruitment finished	
83	17/WM/0246	220487	Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting.	Number Agreed	5	5	Date Agreed	31/05/2018	5	31/05/2018	5	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
84	17/LO/1461	230430	A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals' investigational vaccine GSK3277511A when administered intramuscularly according to a 0, 2 months schedule in COPD patients aged 40 to 80 years with a previous history of acute exacerbation (AECOPD).	Range Agreed	3	10	Date Agreed	08/06/2018	3	08/06/2018	3	Recruitment finished	
85	18/LO/0112	238122	A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years	Range Agreed	1	6	Date Agreed	31/05/2018	1	16/05/2018	1	Recruitment finished	
86	14/WS/1113	153352	A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira®(Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD)	Number Agreed	3	3	Date Agreed	30/04/2020	3	01/03/2018	3	Recruitment finished	
87	15/WM/0363	184648	A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, MulticenterStudy Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis.	Number Agreed	2	2	Date Agreed	30/06/2018	2	30/06/2018	2	Recruitment finished	
88	15/YH/0483	191668	Single Arm Study to Assess the Efficacy of UVADEX (methoxsalen) Sterile Solution in conjunction with the Therakos CELLEX Photopheresis system in Pediatric Patients with steroid-refractory Acute Graft versus Host Disease (aGvHD)	Number Agreed	1	1	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment finished	
89	17/LO/1571	230731	A Prospective observational study of paediatric patients affected by haematological disorders treated with matched unrelated donor stem cell transplant	Range Agreed	2	5	Date Agreed	01/07/2018	4	30/06/2018	4	Recruitment finished	
90	14/WM/0182	153362	A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren's syndrome	Range Agreed	3	7	Date Agreed	30/04/2018	5	30/04/2018	5	Recruitment finished	